Parasympathetic suppression of manic symptoms by physostigmine.
D000109:Acetylcholine / Q000378:metabolism; D000328:Adult; D000339:Affect / Q000187:drug effects; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009388:Neostigmine / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D010275:Parasympathetic Nervous System / Q000187:drug effects*; D010830:Physostigmine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010919:Placebos; D012075:Remission, Spontaneous; D012559:Schizophrenia / Q000188:drug therapy
D010919:Placebos; D009388:Neostigmine; D010830:Physostigmine; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine